Danaher Corporation $DHR Shares Sold by AE Wealth Management LLC

AE Wealth Management LLC lessened its stake in shares of Danaher Corporation (NYSE:DHR) by 5.7% in the second quarter, according to its most recent filing with the SEC. The fund owned 11,700 shares of the conglomerate’s stock after selling 706 shares during the period. AE Wealth Management LLC’s holdings in Danaher were worth $2,311,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Nuveen LLC bought a new position in Danaher during the first quarter valued at about $833,941,000. Invesco Ltd. lifted its position in Danaher by 44.5% during the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate’s stock valued at $965,259,000 after purchasing an additional 1,450,703 shares during the period. Baird Financial Group Inc. boosted its position in shares of Danaher by 290.6% in the 1st quarter. Baird Financial Group Inc. now owns 1,441,706 shares of the conglomerate’s stock worth $295,550,000 after purchasing an additional 1,072,617 shares during the last quarter. Generation Investment Management LLP boosted its position in shares of Danaher by 33.2% during the first quarter. Generation Investment Management LLP now owns 3,178,124 shares of the conglomerate’s stock worth $651,515,000 after purchasing an additional 791,662 shares in the last quarter. Finally, Parnassus Investments LLC grew its stake in Danaher by 23.3% in the first quarter. Parnassus Investments LLC now owns 3,828,024 shares of the conglomerate’s stock valued at $784,745,000 after acquiring an additional 722,636 shares during the period. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Danaher

In related news, Director Teri List sold 2,778 shares of the business’s stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the completion of the sale, the director owned 20,751 shares of the company’s stock, valued at approximately $4,379,706.06. The trade was a 11.81% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 11.10% of the company’s stock.

Danaher Price Performance

DHR opened at $215.80 on Wednesday. The firm has a market capitalization of $152.43 billion, a PE ratio of 44.49, a price-to-earnings-growth ratio of 3.28 and a beta of 0.81. Danaher Corporation has a 1 year low of $171.00 and a 1 year high of $258.23. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.52 and a quick ratio of 1.10. The business’s 50-day moving average is $204.36 and its two-hundred day moving average is $200.64.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, October 21st. The conglomerate reported $1.89 earnings per share for the quarter, beating analysts’ consensus estimates of $1.72 by $0.17. The firm had revenue of $6.05 billion for the quarter, compared to analyst estimates of $6 billion. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The business’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same period in the previous year, the company earned $1.71 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Research analysts anticipate that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, October 31st. Shareholders of record on Friday, September 26th were given a dividend of $0.32 per share. The ex-dividend date was Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. Danaher’s dividend payout ratio is currently 26.39%.

Wall Street Analysts Forecast Growth

DHR has been the subject of several recent analyst reports. Deutsche Bank Aktiengesellschaft upped their price objective on shares of Danaher from $235.00 to $250.00 and gave the stock a “buy” rating in a research report on Wednesday, October 22nd. TD Cowen increased their target price on shares of Danaher from $250.00 to $260.00 and gave the stock a “buy” rating in a research report on Wednesday, October 22nd. Wall Street Zen cut shares of Danaher from a “buy” rating to a “hold” rating in a research report on Monday. Guggenheim reissued a “buy” rating and set a $250.00 price objective on shares of Danaher in a research note on Wednesday, July 23rd. Finally, Bank of America decreased their price objective on shares of Danaher from $230.00 to $220.00 and set a “buy” rating for the company in a report on Monday, September 22nd. Eighteen analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $243.39.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.